Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Respiri. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Respiri's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Respiri has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Respiri's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Respiri's earnings growth to the Australia market average as no estimate data is available.
Unable to compare Respiri's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if Respiri is high growth as no earnings estimate data is available.
Unable to determine if Respiri is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Respiri's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Mario Gattino serves as Executive Director of Respiri Limited since December 14, 2017. He has been the Chief Executive Officer at Respiri Limited since December 1, 2017. Mr. Gattino served as Country Chief Executive Officer in Budapest including responsibility for logistics and distribution in central and Eastern Europe. His latest role was Vice President and General Manager (ANZ) for Ikaria Inc., where he turned around its Australia and New Zealand business and was responsible for spearheading an expansion into APAC. Other key roles he has held include Managing Director for Perrigo ANZ, a company that makes a wide range of consumer healthcare products and was the key advisor to an in- vitro diagnostic start-up where he developed its global commercialisation strategy and successfully raised capital. Mr. Gattino has over 25 years' experience in senior leadership positions within the medical industry. He has held senior leadership positions at Pfizer. He has a long successful track record in commercializing drug and device products globally and growing sales in multiple markets including the USA, Europe and Asia. He is an expert in sophisticated stakeholder management, portfolio and business development via M&A and licensing, brand commercialization, business innovation and profit generation. His experience in launching and managing products in several countries, formulating and executing commercialization plans and dealing with local regulators be invaluable to Respiri at this important juncture, he spent 20 years working with Pfizer including serving as the Chief Operating Officer & Regional Business Director responsible for operational issues in ten Northern European countries. He holds an MBA from the University of NSW (AGSM) and a Bachelor of Applied Science (Medical Administration) from La Trobe University.
Insufficient data for Mario to compare compensation growth.
Mario's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Respiri management team is less than 2 years, this suggests a new team.
Does Respiri Limited (ASX:RSH) Need To Issue More Shares?
Respiri Limited (ASX:RSH) continues its loss-making streak, announcing negative earnings for its latest financial year ending. … Looking at Respiri’s latest financial data, I will gauge when the company may run out of cash and need to raise more money. … View out our latest analysis for Respiri?
All You Need To Know About Respiri Limited's (ASX:RSH) Risks
A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … Based on this beta value, RSH appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … RSH, with its market capitalisation of AUD A$16.90M, is a small-cap stock, which generally have higher beta than similar companies of larger size.
Will Respiri Limited (ASX:RSH) Need To Raise More Money?
With a negative operating cash flow of -$2.91M, RSH is chipping away at its $1.59M cash reserves in order to run its business. … The measure of how fast RSH goes through its cash reserves over time is called the cash burn rate. … The cash burn analysis result indicates a cash constraint for RSH, due to its current level of cash reserves.
Respiri Limited, a health technology company, researches, develops, commercializes, and sells medical devices in Australia and Israel. The company produces and sells mobile health applications. Its products include SonoSentry, an over-the-counter wheeze detection device; and Wholter, a device for home ambulatory recording of nocturnal wheeze and cough. The company also offers PulmoTrack, a computerized wheeze detection product designed for hospital/clinical based real-time monitoring of wheeze and cough in the management of acute asthma in the ER and ICU, and for pediatric pulmonary function testing and sleep labs. In addition, it is developing AirSonea, an app featuring asthma management diary, medication usage and reminders, and symptoms and triggers for asthma sufferers. The company was formerly known as iSonea Limited and changed its name to Respiri Limited in December 2015. Respiri Limited is based in Melbourne, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.